BioSpace News Archive

MDimune Inc., a Korean biotech company developing BioDrone™ platform technology based on cell-derived vesicles (CDVs), announced the publication of data in the Journal of Extracellular Biology showing the development of the Good Manufacturing Practice (GMP)-compliant manufacturing process of CDVs and their biological activities.

Panavance Therapeutics Inc. today announced that Greg Bosch, Chairman and CEO of Panavance Therapeutics will present at the Virtual Investor 2023 Companies to Watch Event on Wednesday, January 18, 2023.

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today the first surgical cases of ARx Spinal Fixation System.

Alveo Technologies, Inc. announced it has signed a Memorandum of Understanding with the Barbados Investment and Development Corporation to co-develop on its novel molecular sensing platform, while contributing to the growth of the life sciences industry in the Caribbean nation.

Noema Pharma announced that members of the Management Team will attend and present at the 41st Annual J.P. Morgan Healthcare Conference taking place on January 9-12, 2023 in San Francisco, CA.

eFFECTOR Therapeutics, Inc. provided an update on its ongoing clinical development programs for both zotatifin, in Phase 2 expansion cohorts for the treatment of estrogen receptor positive breast cancer and KRAS non-small cell lung cancer as well as Phase 1 development for SARS-CoV-2, and tomivosertib, in a Phase 2b trial for the treatment of non-small cell lung cancer in combination with pembrolizumab, an established anti-immune checkpoint inhibitor used to treat various types of cancer.

Tempus, a leader in artificial intelligence and precision medicine, today announced a prospective study (NCT05257551), in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), that aims to identify biomarkers of response in patients with small cell lung cancer (SCLC).

The biotech group Novozymes has invested in a new and energy-friendly filtration replacement from Danish Lyras.

GI Windows Surgical (GIWS), a clinical-stage, privately-held medical device company, announced today the recent publication of a groundbreaking study in the official journal of SURGERY that publishes major trends shaping general surgery and ranks among the most cited journals in its field.

CytomX Therapeutics, Inc. announced its 2023 company priorities and provided a pipeline update which included anticipated milestones for 2023, recent progress and achievements in its wholly owned and collaboration pipeline, and a data update for the Phase 2, CX-2029 cohort expansion study.